https://european-biotechnology.net/wp-content/uploads/2025/11/Alzheimer_semaglutide_483897781_059ZuRgXrKJ8ubHxTiCeiYY6BOdGSl4Z-e1764149601345.jpg433653Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-20 13:38:412026-02-20 13:38:41J&J stops enrollment in an AC Immune-partnered Alzheimer trial, but the reason is not yet clear
https://european-biotechnology.net/wp-content/uploads/2026/02/resource-database-4uUmTpyb5eU-unsplash-1-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-18 16:56:022026-02-18 16:56:02PLL Therapeutics reports positive phase I/II data for gut-targeting ALS therapy
https://european-biotechnology.net/wp-content/uploads/2026/02/v2osk-In4XVKhYaiI-unsplash-1030x658-1.jpg6581030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-18 15:27:202026-02-18 15:27:20Axol buys Newcells’ ophthalmology business to grow drug discovery portfolio
https://european-biotechnology.net/wp-content/uploads/2026/02/igor-omilaev-t4dYnNOUOWc-unsplash-2-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-18 09:09:102026-02-18 09:09:10Compass Pathways clears second phase III hurdle for psilocybin in treatment-resistant depression
